{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:27:23Z","timestamp":1790623643586,"version":"4.1.0"},"reference-count":103,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-term outcomes with tyrosine kinase inhibitors (TKIs) show that their impact on chronic myeloid leukemia (CML) is sustained as shown by 13 studies with 5- to 14-year-follow-up, and numerous shorter-term studies of newly diagnosed chronic-phase CML. Twenty-five years of imatinib (IM) treatment confirm its beneficial effect on survival and possible cure of CML. Large, randomized, academic, treatment-optimization studies have confirmed and extended the pivotal International Randomized Study on Interferon and STI571. The 3 academic trials in Germany, France, and the United Kingdom did not show benefit of the IM-interferon (IFN) combination, despite the immunomodulatory properties of IFN. Second-generation (2G) TKIs induce responses faster than IM and recognize IM-resistance mutations but do not prolong survival compared with IM. Adverse drug-related reactions (ADRs) limit the general use of 2GTKIs despite frequent but mostly mild IM-ADRs. Molecular monitoring of treatment efficacy has been established serving as an example for other neoplasms. Comorbidities, transcript type, and the negative impact of high-risk additional chromosomal abnormalities were addressed. A new prognostic score (European Treatment and Outcome Study long-term survival score) accounts for the fact that the majority of patients with CML die of other causes. Non-CML determinants of survival have been identified. Large and long-term observational studies demonstrate that progress with CML management has also reached routine care in most but not all instances. Despite merits of 2GTKIs, IM remains the preferred treatment option for CML because of its efficacy and superior safety.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026311","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T21:25:29Z","timestamp":1730496329000},"page":"910-920","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-487X","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Guilhot","sequence":"first","affiliation":[{"name":"1INSERM CIC 1402, Universit\u00e9 de Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"2Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany"},{"name":"3European LeukemiaNet Foundation, Weinheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2025032119424072700_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"14","key":"2025032119424072700_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025032119424072700_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2025032119424072700_bib4","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1097\/HS9.0000000000000468","article-title":"Chronic myeloid leukemia in 2020","volume":"4","author":"Hehlmann","year":"2020","journal-title":"Hemasphere"},{"issue":"5","key":"2025032119424072700_bib5","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"issue":"4","key":"2025032119424072700_bib6","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2025032119424072700_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025032119424072700_bib10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025032119424072700_bib16","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2025032119424072700_bib17","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/s41375-020-01117-w","article-title":"Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial","volume":"35","author":"Guilhot","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2025032119424072700_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.17961","article-title":"The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML)","volume":"196","author":"Gallipoli","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2025032119424072700_bib51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study","volume":"28","author":"Cortes","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025032119424072700_bib52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12185-014-1566-2","article-title":"Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the tyrosine kinase inhibitor optimization and selectivity (TOPS) study","volume":"99","author":"Baccarani","year":"2014","journal-title":"Int J Hematol"},{"issue":"2","key":"2025032119424072700_bib53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br J Haematol"},{"issue":"20","key":"2025032119424072700_bib55","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"De Lavallade","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025032119424072700_bib57","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"2025032119424072700_bib58","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"issue":"suppl 15","key":"2025032119424072700_bib59","article-title":"Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily [abstract]","volume":"32","author":"Sasaki","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025032119424072700_bib56","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"2025032119424072700_bib60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12288-018-1009-y","article-title":"Chronic myeloid leukemia: long-term outcome data in the imatinib era","volume":"35","author":"Ganesan","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"9","key":"2025032119424072700_bib61","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1080\/10428194.2022.2068000","article-title":"Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience","volume":"63","author":"Szczepanek","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025032119424072700_bib62","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2025032119424072700_bib63","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2025032119424072700_bib64","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.24591","article-title":"A\u00a0population-based study of chronic myeloid leukemia patients treated with imatinib in first line","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2025032119424072700_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.25306","article-title":"Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am J Hematol"},{"issue":"24","key":"2025032119424072700_bib71","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2025032119424072700_bib72","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the\u00a0dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2025032119424072700_bib75","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2018-99-110128","article-title":"Spirit 2: final 5-year analysis of the UK National Cancer Research Institute randomized study comparing imatinib with dasatinib in patients with newly diagnosed chronic phase CML [abstract]","volume":"132","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"24","key":"2025032119424072700_bib84","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2025032119424072700_bib88","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"28","key":"2025032119424072700_bib92","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032119424072700_bib93","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2025032119424072700_bib94","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025032119424072700_bib95","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"19","key":"2025032119424072700_bib73","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A\u00a0randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2025032119424072700_bib74","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ejh.12423","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)","volume":"94","author":"Hjorth-Hansen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"11","key":"2025032119424072700_bib8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med Overseas Ed"},{"issue":"23","key":"2025032119424072700_bib9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med Overseas Ed"},{"issue":"8","key":"2025032119424072700_bib11","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"5531","key":"2025032119424072700_bib12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"5538","key":"2025032119424072700_bib13","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","article-title":"Roots of clinical resistance to STI-571 cancer therapy","volume":"293","author":"Hochhaus","year":"2001","journal-title":"Science"},{"issue":"15","key":"2025032119424072700_bib14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032119424072700_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2025032119424072700_bib18","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2025032119424072700_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2025032119424072700_bib20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-014-2041-0","article-title":"Older patients with chronic myeloid leukemia (\u2265 65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV","volume":"93","author":"Proetel","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2025032119424072700_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV","volume":"93","author":"Kalmanti","year":"2014","journal-title":"Ann Hematol"},{"issue":"7","key":"2025032119424072700_bib22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"2025032119424072700_bib23","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2025032119424072700_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2025032119424072700_bib25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2025032119424072700_bib97","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","article-title":"Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on CML","volume":"25","author":"Pfirrmann","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2025032119424072700_bib98","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"17","key":"2025032119424072700_bib86","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"2025032119424072700_bib99","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"issue":"16","key":"2025032119424072700_bib101","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","article-title":"Malignancies occurring during therapy\u00a0with tyrosine kinase inhibitors\u00a0(TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2025032119424072700_bib102","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.59","article-title":"Increased prevalence of prior malignancies and autoimmune diseases in patients\u00a0diagnosed with chronic myeloid leukemia","volume":"30","author":"Gunnarsson","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2025032119424072700_bib100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12185-019-02620-2","article-title":"Incidence of second malignancies in\u00a0patients with chronic myeloid leukemia\u00a0in the era of tyrosine kinase inhibitors","volume":"109","author":"Sasaki","year":"2019","journal-title":"Int J Hematol"},{"issue":"11","key":"2025032119424072700_bib26","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","article-title":"Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase","volume":"140","author":"Lauseker","year":"2014","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"2025032119424072700_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025032119424072700_bib28","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"2025032119424072700_bib29","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2025032119424072700_bib30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025032119424072700_bib31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and&gt; 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"35","key":"2025032119424072700_bib32","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2025032119424072700_bib33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2025032119424072700_bib34","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"2025032119424072700_bib35","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2025032119424072700_bib36","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. an international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"issue":"26","key":"2025032119424072700_bib37","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2025032119424072700_bib38","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann Hematol"},{"issue":"10","key":"2025032119424072700_bib39","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/s41375-022-01681-3","article-title":"Impact of emerging ACA on survival in CML","volume":"36","author":"Hehlmann","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2025032119424072700_bib40","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"issue":"13","key":"2025032119424072700_bib41","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/cncr.30636","article-title":"Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death","volume":"123","author":"Lauseker","year":"2017","journal-title":"Cancer"},{"issue":"16","key":"2025032119424072700_bib42","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1182\/blood-2013-11-539742","article-title":"The impact of health care settings on survival time of patients with chronic myeloid leukemia","volume":"123","author":"Lauseker","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025032119424072700_bib43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Sau\u00dfele","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2025032119424072700_bib44","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2025032119424072700_bib45","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2025032119424072700_bib46","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1002\/cncr.28328","article-title":"Tolerability and efficacy of pegylated interferon-\u03b1-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia","volume":"119","author":"Johnson-Ansah","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"2025032119424072700_bib47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2025032119424072700_bib48","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025032119424072700_bib49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025032119424072700_bib54","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00432-017-2385-7","article-title":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second-generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"143","author":"Hoffmann","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"2","key":"2025032119424072700_bib67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14656566.2011.533169","article-title":"Treatment of chronic myeloid leukemia when imatinib fails","volume":"12","author":"Hehlmann","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"5682","key":"2025032119424072700_bib68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"11","key":"2025032119424072700_bib69","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In\u00a0vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"19","key":"2025032119424072700_bib70","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032119424072700_bib76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50\u00a0mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"2025032119424072700_bib77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"2025032119424072700_bib78","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025032119424072700_bib79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"10","key":"2025032119424072700_bib80","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2025032119424072700_bib81","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2025032119424072700_bib82","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph (+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2025032119424072700_bib83","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3324\/haematol.2021.280175","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study","volume":"107","author":"Gugliotta","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"2025032119424072700_bib85","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"2025032119424072700_bib87","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2025032119424072700_bib89","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in\u00a0nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"2025032119424072700_bib90","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","article-title":"A\u00a0phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects","volume":"69","author":"Abbas","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"17","key":"2025032119424072700_bib91","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2025032119424072700_bib96","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","article-title":"Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet","volume":"119","author":"Guilhot","year":"2012","journal-title":"Blood"},{"issue":"7971","key":"2025032119424072700_bib103","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41586-023-06266-3","article-title":"Cancer aneuploidies are shaped primarily by effects on tumour\u00a0fitness","volume":"619","author":"Shih","year":"2023","journal-title":"Nature"},{"key":"2025032119424072700_bib104","author":"Lauseker","year":"22-24  2010"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/910\/2357269\/blood_bld-2024-026311-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/910\/2357269\/blood_bld-2024-026311-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:47:14Z","timestamp":1742590034000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/9\/910\/525850\/Long-term-outcomes-of-tyrosine-kinase-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026311","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}